China Biopharmaceutical Advances Innovation with Strategic Pipeline In-licensing Amid Strong Government Support
Sino Biopharm
Pharmaceutical R&D Developer
Arnatar
Antisense Technology Drug Developer
Haisco
New Drug Research and Development, Production, and Sales
AstraZeneca
Pharmaceutical Technology Research and Development Provider
The policy support for innovative drugs is continuously increasing.
On the evening of April 7, local governments in Beijing, Guangzhou, Zhuhai, and other places simultaneously issued policies to support the high-quality development of innovative pharmaceuticals, with a maximum support amount of 5 billion yuan.
Based on their own advantages, Chinese pharmaceutical companies are actively seeking change.
On April 8, Sino Biopharm announced that it had signed a strategic cooperation agreement with Boehringer Ingelheim. Both parties will leverage their respective strengths and resources to jointly research, develop, and commercialize Boehringer Ingelheim's oncology pipeline in mainland China.
According to the terms of the agreement, this strategic cooperation covers multiple assets of Boehringer Ingelheim in clinical stages, including three assets in clinical development: Brigimadlin, Zongertinib, and the DLL3/CD3 bispecific T-cell engager, as well as several early-stage clinical assets.
In the past day, what are the hot topics worth paying attention to in the pharmaceutical markets at home and abroad? Let Amino take you through them.
/ 01 /
Market Express
1) Multiple provinces and cities introduce policies to support pharmaceutical innovation, with the highest support amount reaching 5 billion yuan
On April 7, governments in multiple locations including Beijing, Guangzhou, and Zhuhai simultaneously issued policies to support the high-quality development of innovative pharmaceuticals, with a maximum support amount of 5 billion yuan.
2) Sino Biopharm and Boehringer Ingelheim Reach Strategic Cooperation
On April 8, Sino Biopharm announced that it had signed a strategic cooperation agreement with Boehringer Ingelheim. Both parties will leverage their respective strengths and resources to jointly develop and commercialize Boehringer Ingelheim's oncology pipeline in mainland China. According to the terms of the agreement, this strategic cooperation covers multiple assets in BI’s clinical stage, including three assets in clinical development — Brigimadlin, Zongertinib, and the DLL3/CD3 bispecific T-cell engager — as well as several early-stage clinical assets.
/ 02 /
Capital Information
1) Arnatar Therapeutics Completes Over $50 Million Series A Financing
On April 8, Arnatar announced that it had recently completed a Series A financing round of over 50 million US dollars. The funds will mainly be used to accelerate the in-depth layout of the company's drug pipeline, rapidly advance clinical trials, and support the operational establishment of its China-based company.
/ 03 /
Pharmaceuticals and Medical Devices Updates
1) Haisco HSK31858 Tablets Approved for Clinical Trials
On April 8, according to the CDE official website, Haisco's HSK31858 tablets have been approved for clinical trials and are intended for the treatment of bronchial asthma.
2) Ruihongdi Pharmaceutical's Injectable RGL-2102 Approved for Clinical Trials
On April 8, according to the CDE official website, Ruihongdi Pharmaceutical's injectable RGL-2102 was approved for clinical trials, intended for the treatment of lower limb ischemic diseases.
3) Hansoh Bio HS-20117 Injection Approved for Clinical Trials
On April 8, according to the CDE official website, HS-20117 Injection developed by Shanghai Hansoh BioMedical Co., Ltd. has been approved for clinical trials. It is proposed to be used in combination with Ameitinib Mesylate Tablets for first-line treatment of advanced-stage locally advanced or metastatic non-squamous NSCLC with EGFR-sensitive mutations.
4) AstraZeneca's Budesonide/Formoterol Inhalation Aerosol Approved for Clinical Use in China
On April 8, according to the CDE official website, AstraZeneca's Budesonide/Glycopyrronium/Formoterol inhalation aerosol has been approved for clinical trials. It is intended for use in COPD patients who are still experiencing exertional dyspnea despite having received single-agent or dual-agent COPD maintenance therapy.
5) Amgen's AMG 193 Approved for Clinical Trials in China
On April 8, according to the CDE website, Amgen's AMG 193 has been approved for clinical trials, intended for the treatment of adult patients with advanced solid tumors deficient in methylthioadenosine phosphorylase.
6) PT217 from Fanent Pharmaceuticals Approved for Clinical Trials
On April 8, according to the CDE official website, PT217 developed by Phanes Therapeutics was approved for clinical trials and is proposed for conducting research on the treatment of advanced solid tumors.
7) Qilu Pharmaceutical's QLC1101 Capsule Approved for Clinical Trials
On April 8, according to the CDE official website, Qilu Pharmaceutical's QLC1101 capsule has been approved for clinical trials, intended for use in advanced solid tumors carrying the KRAS G12D mutation.
8) Hengrui Medicine's HRS2398 Sustained-Release Tablets Approved for Clinical Trials
On April 8, according to the CDE official website, HRS2398 Sustained-Release Tablets developed by Hengrui Medicine were approved for clinical trials, intended for the treatment of patients with advanced malignant tumors.
9) DualityBio's DB-1303 Injection Approved for Clinical Use
On April 8, according to the CDE official website, Duality Biologics' DB-1303 Injection has been approved for clinical trials, intended for HER2-positive inoperable/metastatic breast cancer.
Text by Huang Kai
PS: Welcome to scan the QR code below and add the WeChat ID of AminoGenius for communication.
